tamoxifen / Generic mfg. - LARVOL DELTA

FINAL OVERALL SURVIVAL RESULTS FROM THE GOG281/LOGS STUDY EVALUATING TRAMETINIB VERSUS PHYSICIAN'S CHOICE STANDARD-OF-CARE THERAPY FOR RECURRENT LOW-GRADE SEROUS OVARIAN CANCER (LGSOC) (IGCS 2025) - P2/3 | " This international phase 2/3 trial randomly assigned (1:1) patients with recurrent LGSOC to receive either oral trametinib 2 mg once daily (n=130) or one of five SoC treatment options (n=130): intravenous paclitaxel 80 mg/m² by body surface area on days 1, 8, and 15 of every 28-day cycle; intravenous pegylated liposomal doxorubicin 40–50 mg/m² once every 4 weeks; intravenous topotecan 4 mg/m² on days 1, 8, and 15 of every 28-day cycle; oral letrozole 2·5 mg once daily; or oral tamoxifen 20 mg twice daily. At the time of the final analysis, 29 (22.3%) patients in the trametinib arm and 15 (11.5%) patients in the SoC arm remained alive. The median OS was 36.4 months in the trametinib arm versus 29.8 months in the SoC arm (HR 0.68; 95% CI 0.49-0.94; p=0.018, 1-sided), despite the fact that 72% of patients in the SoC arm crossed over to trametinib following progression. In the 93 SoC patients who crossed over to trametinib the median PFS..."

Clinical • Late-breaking abstract • Oncology • Ovarian Cancer • Ovarian Serous Adenocarcinoma • Solid Tumor

Adropin Reduces Early Brain Injury and Delayed Cerebral Ischemia After Severe Subarachnoid Hemorrhage in a Mouse Model. (PubMed, J Am Heart Assoc) - "Adropin confers robust neurovascular protection after severe SAH when administered within a clinically relevant early therapeutic window. These findings highlight adropin as a promising candidate for mitigating endothelial dysfunction, vasospasm, and long-term neurological deficits following SAH, with timing of intervention playing a critical role in therapeutic efficacy."

Journal • Preclinical • Cardiovascular • CNS Disorders • Hematological Disorders • Psychiatry • Subarachnoid Hemorrhage • Thrombosis • Vascular Neurology • NOS3 • OCLN

Endocrine therapy adherence and 10-year cardiometabolic risk in hormone receptor-positive breast cancer. (PubMed, JNCI Cancer Spectr) - "AI adherence was associated with increased cardiometabolic risk, whereas TAM was associated only with hypertension risk. Despite these risks, AET was associated with improved survival. Further research should evaluate whether cardiometabolic risk factors influence cardiovascular events among BC survivors."

Journal • Breast Cancer • Cardiovascular • Diabetes • Dyslipidemia • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • Hypertension • Metabolic Disorders • Oncology • Solid Tumor

Reassessing the Role of Progenitor Cells in Muscle Wasting in Cancer Cachexia. (PubMed, Am J Physiol Cell Physiol) - "Colon-26 (C-26) carcinoma cells were injected into adult (≥12-weeks-old) Pax7-CreER; Rosa26-LSL-tdTomato mice, and tamoxifen was administered after tumors were established but prior to cachexia...When we repeated Pax7-lineage tracing and scRNA-seq on young mice (6-week-old) still undergoing developmental muscle growth similar results were obtained, but interestingly, by flow cytometry we detected a small population of Sca1+; tdTomato+ cells, not present in adult muscles. Thus, non-myogenic progenitors might indeed be capable of adopting a myogenic fate during cancer cachexia, but this contributes to only a minor fraction of Pax7+ cells and likely to be age dependent."

Journal • Cachexia • Colon Cancer • Oncology • Solid Tumor • PAX7 • PDGFRA

The effect of tamoxifen on haematological parameters and iron status in laying hens. (PubMed, Poult Sci) - "The findings suggest a correlation between hormonal regulation, erythropoiesis, and iron metabolism in hens. The results of this study underscore the importance of considering endocrine factors in the interpretation of haematological parameters of laying hens."

Journal • Hematological Disorders • Metabolic Disorders

Investigation of the Relationship Between CYP2D6, BRCA1, BRCA2, TP53, and GSTP1 Gene Mutations and Tamoxifen Resistance in Breast Cancer Patients (ESMO 2026) - No abstract available

Clinical • Breast Cancer • Oncology • Solid Tumor • BRCA1 • BRCA2 • GSTP1 • TP53

Clinical Outcomes of De Novo Oligometastatic Breast Cancer Patients Treated with Curative Intent (ASTRO 2026) - "For ER+ patients, 94% received tamoxifen or aromatase inhibitors, and 69% received CDK4/6 inhibitors... Definitive treatment of synchronous oligometastatic breast cancer resulted in durable local control in our series with approximately half of patients noting progression by 5 years. Prospective investigation is warranted to better define optimal patient selection and treatment strategies for oligometastatic breast cancer."

Clinical • Clinical data • Metastases • Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • HER2 Positive Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer • HER-2

Thrombophilia Screening Prior to Tamoxifen Therapy in Early-Stage Hormone Receptor-Positive Breast Cancer: A Three-Year Retrospective Study (ESMO 2026) - No abstract available

Retrospective data • Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor

Novel p53 Variants and Tamoxifen Resistance in Breast Cancer (ESMO 2026) - No abstract available

Breast Cancer • Oncology • Solid Tumor

Lysine acetyltransferase 6A (KAT6A) for predicting tamoxifen resistance in hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) early breast cancer (EBC) (ESMO 2026) - No abstract available

Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • HER2 Positive Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor • HER-2 • KAT6A

Giredestrant vs standard-of-care endocrine therapy as adjuvant treatment for patients with estrogen receptor-positive, HER2-negative early breast cancer: Results from the global Phase III lidERA Breast Cancer trial (SABCS 2025) - P3 | "Giredestrant, a next-generation oral selective estrogen receptor antagonist and degrader (SERD), was shown to be more potent than other SERDs (Liang 2021; Bardia 2023) and demonstrated superior antiproliferative activity vs anastrozole in the neoadj coopERA BC trial (Hurvitz 2023)... Pts with Stage I-III ER+ HER2- eBC were randomized 1:1 to giredestrant 30 mg oral daily (with an LHRH agonist in pre- and peri-menopausal women, and men) or standard-of-care ET (tamoxifen or aromatase inhibitor) for 5 years (yr)... lidERA BC is the first Phase III trial to demonstrate benefit with an oral SERD in eBC. Giredestrant tx resulted in a statistically significant and clinically meaningful IDFS improvement vs standard-of-care ET in ER+, HER2- eBC. OS trended in favor of the giredestrant arm, and DRFI was improved vs standard-of-care ET."

Clinical • P3 data • Breast Cancer • Estrogen Receptor Positive Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • HER2 Positive Breast Cancer • Hormone Receptor Breast Cancer • Oncology • Solid Tumor • ER • HER-2

The effect of adding ovarian function suppression to adjuvant endocrine therapy in premenopausal patients with hormone receptor-positive, HER2-positive breast cancer who have undergone neoadjuvant therapy: a single-center experience. (PubMed, BMC Cancer) - "In this retrospective real-world study, no independent association between OFS and survival outcomes was observed in premenopausal patients with HR-positive/HER2-positive breast cancer treated with anti-HER2-based neoadjuvant therapy. Patients achieving pCR had excellent prognoses regardless of OFS use. Given the limited statistical power and the predominantly tamoxifen-treated cohort, these findings should be interpreted with caution. Prospective studies are warranted to better define the role of OFS in this patient population."

Journal • Retrospective data • Breast Cancer • HER2 Breast Cancer • HER2 Positive Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor • HER-2

Esophageal Parakeratosis Mimicking Squamous Neoplasia in a Patient With Multiple Field Cancerization Risk Factors (ACG 2026) - "Case Description/ A 79-year-old woman with chronic GERD on omeprazole, longstanding remote tobacco use (quit 18 years prior), regular alcohol intake, frequent NSAID use, neurofibromatosis, and prior stage IA invasive ductal carcinoma treated with lumpectomy and 5 years of tamoxifen presented for workup of >10% unintentional weight loss (164 to 144 lb), early satiety, and refractory reflux. (B) High-power view (40x) demonstrating parakeratosis with retained pyknotic nuclei within the keratin layer. No dysplasia or intraepithelial eosinophils were identified."

Clinical • Gastroenterology • Gastroesophageal Reflux Disease • Genetic Disorders • Neurofibromatosis • Oncology • Solid Tumor • Squamous Cell Carcinoma

A Rare Case of Three Distinct Primary Malignancies in a Postmenopausal Woman (ACG 2026) - "Stereotactic biopsy confirmed estrogen receptor/progesterone receptor-positive ductal carcinoma in situ (DCIS), which was treated with lumpectomy, adjuvant radiation therapy, and tamoxifen...This case highlights the importance of maintaining clinical suspicion when pathology and imaging findings are discordant, particularly in patients with complex oncologic histories. Long-term surveillance, multidisciplinary collaboration, and individualized management strategies remain critical for optimizing outcomes in cancer survivors who develop primary malignancies in patients with multiple primary malignancies and rare tumor histologies."

Clinical • Cervical Adenocarcinoma • Cervical Cancer • Esophageal Adenocarcinoma • Gastrointestinal Disorder • Gynecology • Oncology • Solid Tumor • ER • HER-2 • PGR

Encapsulating Sclerosing Mesenteritis Related to Peritoneal Dialysis (ACG 2026) - "In the prior year, he had several episodes of subclinical PD peritonitis manifested as symptoms including abdominal pain, reflux and early satiety, with fluid cultures positive Kocuria rhizophila, treated with vancomycin...He declined tamoxifen and corticosteroids trials and was managed supportively with TPN and palliative care services...Providers should be aware that recurrent episodes of subclinical peritonitis may be a catalyst for chronic peritoneal injury, and that EPS frequently occurs after discontinuation of peritoneal dialysis or renal transplant, hypothesized as an âacute triggerâ. Figure: Image 1 CT images showing 1a (left) Dilation of small bowel indicative of small bowel obstruction, 1b (right) new large fluid and gas-containing collection in the upper abdomen measuring up to 24 cm raising concern for abscess in the setting of perforated hollow viscus with small bowel obstruction Figure: Image 2: Endoscopic findings from December 2025 endoscopy..."

Chronic Kidney Disease • Constipation • Diabetes • Diabetic Nephropathy • Fibrosis • Gastroenterology • Gastrointestinal Disorder • Hepatology • Immunology • Inflammation • Inflammatory Arthritis • Metabolic Disorders • Metabolic Dysfunction-Associated Steatotic Liver Disease • Nephrology • Renal Disease • Rheumatoid Arthritis • Type 2 Diabetes Mellitus

An Ascitic Mystery: Unmasking Sclerosing Mesenteritis (ACG 2026) - "Given the patientâs persistent symptoms and negative workup for malignancy or TB, empiric treatment for suspected SM was initiated with prednisone and tamoxifen...Alternative agents such as azathioprine, pentoxifylline, cyclophosphamide, and thalidomide have also been used with varying success. Obstructive symptoms need conservative therapy or surgical bypass if necessary. Figure: CT image depicting partially calcified sclerosing mesenteritis mass"

Cardiovascular • Fibrosis • Gastrointestinal Disorder • Hematological Malignancies • Immunology • Infectious Disease • Lymphoma • Neuroendocrine Tumor • Respiratory Diseases • Solid Tumor • Tuberculosis

Caught in a Cocoon: Recurrent Small Bowel Obstruction Due to Sclerosing Peritonitis (ACG 2026) - "Proposed management includes corticosteroids in the inflammatory phase and tamoxifen during the fibrotic stage...Figure: Figure 1: Contrast enhanced CT demonstrating clustered small bowel loops surrounded by loculated ascites. Figure: Figure 2: Contrast enhanced CT showing clustered small bowel loops surrounded by ascites with multiple air-fluid levels"

Constipation • Fibrosis • Gastroenterology • Gastrointestinal Disorder • Hepatology • Immunology

Management Approaches for Immune Checkpoint Inhibitor-Induced Sclerosing Mesenteritis: A Case Series (ACG 2026) - "Patient 2: A 48-year-old woman developed abdominal pain and high-grade fevers after one cycle of Nivolumab and Ipilimumab for recurrent metastatic melanoma...Her symptoms were unresponsive to prednisone 40 mg daily and Tamoxifen 10 mg twice daily but improved with ustekinumab...Pembrolizumab was discontinued, and tamoxifen with steroids was continued for two months, with follow-up CT confirming complete resolution ICI-induced sclerosing mesenteritis is a rare immune-related adverse event that can mimic malignancy, enteritis, or infection...1 Timeline treatment events diagram of Case 1 ICI-induced Sclerosing mesenteritis Figure: Figure. 2 Timeline treatment figure of Case 2 ICI-induced Sclerosing mesenteritis"

Checkpoint inhibition • Clinical • Constipation • Gastroenterology • Gastrointestinal Disorder • Genito-urinary Cancer • Immunology • Infectious Disease • Melanoma • Oncology • Renal Cell Carcinoma • Sarcoma • Solid Tumor

Gastrointestinal Neoplasia and Screening Patterns in Patients With MASLD: A Propensity-Matched Cohort Study (ACG 2026) - "Those with prior extrahepatic malignancy and other causes of hepatic steatosis, including alcohol use disorder, chronic hepatitis C infection, celiac disease, hemochromatosis, and long-term use of steatosis-associated medications (systemic corticosteroids, methotrexate, tamoxifen, or amiodarone) were excluded. MASLD was associated with significantly higher risk of colorectal polyps (20.6% vs 6.1%; RR 3.37, OR 3.99; p< 0.001), increased hazard (HR 3.36, p< 0.001), and reduced polyp-free survival (65.2% vs 85.0%). MASLD patients also had a higher number of polyp events (mean 3.74 vs 2.43; p< 0.001). CRC screening utilization was higher in MASLD patients (29.2% vs 12.3%; RR 2.38, OR 2.94; p< 0.001), with increased screening over time (HR 2.49, p< 0.001), though screening-free survival remained lower (50.4% vs 68.9%)."

Clinical • Addiction (Opioid and Alcohol) • Barrett Esophagus • Celiac Disease • Colonic Polyps • Colorectal Cancer • Gastrointestinal Cancer • Gastrointestinal Disorder • Genetic Disorders • Hepatitis C • Hepatocellular Cancer • Hepatology • Immunology • Infectious Disease • Metabolic Disorders • Metabolic Dysfunction-Associated Steatotic Liver Disease • Solid Tumor

Venous Thromboembolism in Patients With Sclerosing Mesenteritis Treated With Tamoxifen: A Matched Retrospective Cohort Study (ACG 2026) - "We included 40 patients diagnosed with SM and treated with tamoxifen and 80 matched controls diagnosed with SM but not treated with tamoxifen. Mean age ( p =0.91) and sex ( p =1.0) were similar between groups (Table 1). VTE occurred in 11/40 SM patients treated with tamoxifen compared with 8/80 controls (27.5% vs 10%, p= 0.018)."

Retrospective data • Breast Cancer • Cardiovascular • Respiratory Diseases • Solid Tumor • Venous Thromboembolism

ImmunoADAPT: Neoadjuvant Endocrine Therapy, Palbociclib, Avelumab in Estrogen Receptor Positive Breast Cancer (clinicaltrials.gov) - P2 | N=33 | Active, not recruiting | Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Trial completion date: Dec 2026 ➔ Mar 2027 | Trial primary completion date: Sep 2026 ➔ Dec 2026

Trial completion date • Trial primary completion date • Breast Cancer • Estrogen Receptor Positive Breast Cancer • Hormone Receptor Positive Breast Cancer • Immune Modulation • Immunology • Oncology • Solid Tumor • ER

Sparse Cell Labeling Reveals Morphologic Diversity Among Mouse Scleral Fibroblasts. (PubMed, Invest Ophthalmol Vis Sci) - "This enables tamoxifen-induced recombination of the Brainbow 2.1 cassette, inducing random expression of fluorescent proteins in all cells...Sparse cell labeling allowed visualization of individual cell morphology in the scleral environment. Cells demonstrated diverse morphologies, and PPS cells responded to IOP elevation."

Journal • Preclinical • Glaucoma • Ophthalmology

Challenges in Developing a Microglial NF-Kappa B Conditional Mouse Model for Glioblastoma Studies. (PubMed, Cells) - "Overall, the data from this study show minimal p65 deletion in microglia from tamoxifen-treated p65fl/fl/CX3CR1creER/+ mice. The limitations of this model will serve as guidance to the GBM TME field for future animal model production."

Journal • Preclinical • Brain Cancer • Glioblastoma • Oncology • Solid Tumor • CX3CR1 • RELA

A new conditional mouse model for Cre-mediated restoration of Hprt1 expression during brain development. (PubMed, bioRxiv) - "Using the ubiquitous tamoxifen-inducible CAG-CreER driver, a single maternal tamoxifen dose at embryonic day (E)8.5 restored whole-brain Hprt1 mRNA expression and HGprt enzyme activity in E14.5 embryos to 72.4% and 13.4% of wild-type levels, respectively...These findings establish the conditional Hprt1 tm1.1(LoxP-mCherry-Stop-LoxP)Vsr mouse as a model for investigating when and where Hprt1 restoration could rescue abnormal brain development, while demonstrating that Cre-driver properties determine experimental specificity and longitudinal feasibility. Beyond LND, this conditional reactivation strategy provides an approach for defining developmental windows of reversibility and lineage-specific requirements for gene restoration in monogenic neurodevelopmental disorders."

Journal • Preclinical • CNS Disorders • Developmental Disorders • Psychiatry • HPRT1

Sexual/intimate morbidity under tamoxifen and risk of weakened treatment adherence in premenopausal women with HR+ breast cancer: An underestimated and potentially modifiable factor (PubMed, Bull Cancer) - "Sexual/intimate morbidity associated with tamoxifen is an underestimated but modifiable factor that weakens treatment adherence. Screening for it through a simple interview and its routine integration into supportive oncology care are two recommended levers for secondary and tertiary prevention of breast cancer by optimizing tamoxifen adherence and quality of life."

Journal • Breast Cancer • Fatigue • Hormone Receptor Breast Cancer • Oncology • Solid Tumor